secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2026-08-14T12:00:16+00:00
Accession:  0001193125-26-350445
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma Q2 net loss $18.1M; completes PYNNACLE enrollment, NDA planned Q1 2027
--------------------------------------------------------------------------------

- Net loss $18.1M for Q2 2026 vs $21.2M in Q2 2025; R&D expenses down to $14.7M from $18.4M.
- Enrollment completed for primary analysis in Phase 2 monotherapy portion of PYNNACLE trial for platinum-resistant/refractory ovarian cancer.
- NDA submission for rezatapopt accelerated approval planned Q1 2027.
- Cash $79.4M as of June 30, 2026, down from $112.9M at Dec 31, 2025; runway through Q2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312526350445/0001193125-26-350445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312526350445/pmvp-20260814.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-350445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer